272 related articles for article (PubMed ID: 34123828)
1. Comprehensive Analysis of GLUT1 Immune Infiltrates and ceRNA Network in Human Esophageal Carcinoma.
Liu XS; Gao Y; Wu LB; Wan HB; Yan P; Jin Y; Guo SB; Wang YL; Chen XQ; Zhou LM; Yang JW; Kui XY; Liu XY; Pei ZJ
Front Oncol; 2021; 11():665388. PubMed ID: 34123828
[TBL] [Abstract][Full Text] [Related]
2. Comprehensive Analysis of Hexokinase 2 Immune Infiltrates and m6A Related Genes in Human Esophageal Carcinoma.
Liu XS; Liu JM; Chen YJ; Li FY; Wu RM; Tan F; Zeng DB; Li W; Zhou H; Gao Y; Pei ZJ
Front Cell Dev Biol; 2021; 9():715883. PubMed ID: 34708035
[No Abstract] [Full Text] [Related]
3. Comprehensive Analysis of YTHDF1 Immune Infiltrates and ceRNA in Human Esophageal Carcinoma.
Liu XS; Kui XY; Gao Y; Chen XQ; Zeng J; Liu XY; Zhang Y; Zhang YH; Pei ZJ
Front Genet; 2022; 13():835265. PubMed ID: 35401696
[No Abstract] [Full Text] [Related]
4. SLC2A1 is a Diagnostic Biomarker Involved in Immune Infiltration of Colorectal Cancer and Associated With m6A Modification and ceRNA.
Liu XS; Yang JW; Zeng J; Chen XQ; Gao Y; Kui XY; Liu XY; Zhang Y; Zhang YH; Pei ZJ
Front Cell Dev Biol; 2022; 10():853596. PubMed ID: 35399515
[No Abstract] [Full Text] [Related]
5. Functional enrichment analysis reveals the involvement of DARS2 in multiple biological pathways and its potential as a therapeutic target in esophageal carcinoma.
Liu XS; Liu ZY; Zeng DB; Hu J; Chen XL; Gu JL; Gao Y; Pei ZJ
Aging (Albany NY); 2024 Feb; 16(4):3934-3954. PubMed ID: 38382106
[TBL] [Abstract][Full Text] [Related]
6. Bridging Integrator 3 (BIN3) Downregulation Predicts a Poor Prognosis in Patients with Esophagus Carcinoma: A Study based on TCGA Data.
Li D; Deng W; Huang G; Xiao X
Comb Chem High Throughput Screen; 2023; 26(11):1974-1989. PubMed ID: 36475339
[TBL] [Abstract][Full Text] [Related]
7. High expression of caspase-8 as a predictive factor of poor prognosis in patients with esophageal cancer.
Chai J; Lei Y; Xiang X; Ye J; Zhao H; Yi L
Cancer Med; 2023 Mar; 12(6):7651-7666. PubMed ID: 36533709
[TBL] [Abstract][Full Text] [Related]
8. Integrated Analysis of CD1A Immune Infiltration and Competing Endogenous RNA Networks in COAD.
Xu H; Zhang H; Sun S; Zhang J; Huo J; Zhou C
Int J Gen Med; 2024; 17():2037-2053. PubMed ID: 38751492
[TBL] [Abstract][Full Text] [Related]
9. NPM1 Is a Prognostic Biomarker Involved in Immune Infiltration of Lung Adenocarcinoma and Associated With m6A Modification and Glycolysis.
Liu XS; Zhou LM; Yuan LL; Gao Y; Kui XY; Liu XY; Pei ZJ
Front Immunol; 2021; 12():724741. PubMed ID: 34335635
[TBL] [Abstract][Full Text] [Related]
10. m6A reading protein RBMX as a biomarker for prognosis and tumor progression in esophageal cancer.
Tuersun H; Liu L; Zhang J; Maimaitizunong R; Tang X; Li H
Transl Cancer Res; 2023 Sep; 12(9):2319-2335. PubMed ID: 37859733
[TBL] [Abstract][Full Text] [Related]
11. Screening of potential key genes in esophageal cancer based on RBP and expression verification of HENMT1.
Reyimu A; Xing F; Zhou W; Zheng Y; Liu B; Dai J; Xing Y; Gao J
Medicine (Baltimore); 2023 Dec; 102(49):e36544. PubMed ID: 38065897
[TBL] [Abstract][Full Text] [Related]
12. Nucleophosmin 1 is a prognostic marker of gastrointestinal cancer and is associated with m6A and cuproptosis.
Liu XS; Liu C; Zeng J; Zeng DB; Chen YJ; Tan F; Gao Y; Liu XY; Zhang Y; Zhang YH; Pei ZJ
Front Pharmacol; 2022; 13():1010879. PubMed ID: 36188614
[No Abstract] [Full Text] [Related]
13. METTL3 as a novel diagnosis and treatment biomarker and its association with glycolysis, cuproptosis and ceRNA in oesophageal carcinoma.
Liu XS; Zhang Y; Liu ZY; Gao Y; Yuan LL; Zeng DB; Tan F; Wan HB; Pei ZJ
J Cell Mol Med; 2024 Mar; 28(6):e18195. PubMed ID: 38429907
[TBL] [Abstract][Full Text] [Related]
14. Integrated analysis of ceRNA network and tumor-infiltrating immune cells in esophageal cancer.
Chen Y; Zhou H; Wang Z; Huang Z; Wang J; Zheng M; Ni X; Liu L
Biosci Rep; 2021 May; 41(5):. PubMed ID: 33960364
[TBL] [Abstract][Full Text] [Related]
15. Overexpression of METTL3 associated with the metabolic status on
Liu XS; Yuan LL; Gao Y; Zhou LM; Yang JW; Pei ZJ
J Cancer; 2020; 11(16):4851-4860. PubMed ID: 32626532
[No Abstract] [Full Text] [Related]
16.
Liu SP; Li XM; Liu DM; Xie SH; Zhang SB; Li Y; Xie ZF
Front Oncol; 2022; 12():884448. PubMed ID: 35530327
[TBL] [Abstract][Full Text] [Related]
17. RAB39B as a Chemosensitivity-Related Biomarker for Diffuse Large B-Cell Lymphoma.
Xu C; Liang T; Liu J; Fu Y
Front Pharmacol; 2022; 13():931501. PubMed ID: 35910358
[No Abstract] [Full Text] [Related]
18. Integrated analysis of competing endogenous RNA in esophageal carcinoma.
Chen N; Wang Z; Yang X; Geng D; Fu J; Zhang Y
J Gastrointest Oncol; 2021 Feb; 12(1):11-27. PubMed ID: 33708421
[TBL] [Abstract][Full Text] [Related]
19. Stemness-related gene signature for predicting therapeutic response in patients with esophageal cancer.
Zhu S; Zhang G; You Q; Li F; Ding B; Liu F; Bi D; Jiang L
Transl Cancer Res; 2022 Jul; 11(7):2359-2373. PubMed ID: 35966312
[TBL] [Abstract][Full Text] [Related]
20. Integrated Analysis of Hub Genes and Pathways In Esophageal Carcinoma Based on NCBI's Gene Expression Omnibus (GEO) Database: A Bioinformatics Analysis.
Yu-Jing T; Wen-Jing T; Biao T
Med Sci Monit; 2020 Aug; 26():e923934. PubMed ID: 32756534
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
